Spyglass Pharma (NASDAQ:SGP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Spyglass Pharma (NASDAQ:SGP) to a hold rating in a research report sent to investors on Tuesday.

Spyglass Pharma Stock Down 1.9%

NASDAQ:SGP opened at $27.69 on Tuesday. Spyglass Pharma has a 52 week low of $20.16 and a 52 week high of $32.44.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the completion of the purchase, the director directly owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).